Advanced Filters
noise

Versailles, France Clinical Trials

A listing of Versailles, France clinical trials actively recruiting patients volunteers.

Found 458 clinical trials
F François GODART

OPTImal Treatment of Sinus VENOSUS Defect

Sinus venosus defect (SVD) accounts for 10% of atrial septal defects and is characterized by an anomalous pulmonary venous return in the superior vena cava associated with a high situated atrial septal defect. Since 2013, transcatheter correction of this congenital heart disease has emerged as a new treatment option. The …

12 years of age All Phase N/A
M Meric BEN BOUJEMA

Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction

It has been demonstrated that sexual activity was common in the majority of men over 50 years old and was an important component of overall quality of life (QoL). Ejaculatory dysfunction (EjD) is the most common side effect of surgical treatment of benign prostatic obstruction (BPO). It has been considered …

40 years of age Male Phase N/A

HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome

The primary objective is to demonstrate the superiority of arginine-vasopressin (AVP) and hydrocortisone compared with norepinephrine regarding day-30 survival and neurological recovery in post-cardiac arrest patients with hemodynamic failure.

18 years of age All Phase 3
N Nathalie BODDAERT, MD, PhD

Understanding the Mechanisms of Autism : an MRI and Social Cognition Study

The main goal of this study is to investigate anatomo-functional brain abnormalities associated with autism spectrum disorders using a multimodal brain imaging approach, as well as its links to social cognition difficulties measured using eye-tracking

3 - 28 years of age All Phase N/A

Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)

The study team hypothesize that non-diabetic patients with Myotonic dystrophy type I (DM1) will improve their symptoms, especially their motor deficit which is the main feature of the disease, because of the splicing defect correction by metformin. The primary objective of the study is to evaluate the efficacy of metformin …

18 - 70 years of age All Phase 3
R REBECA MARTIN ROSIQUE, PhD

Boosting Microbiota Butyrate Producers to Improve Gut Health

The human gut microbiota is a dynamic ecosystem essential to health, influenced by diet, age, and lifestyle. It plays a key role in digestion, immunity, and nervous system regulation. Among its important compounds, short-chain fatty acids, particularly butyrate, are crucial for intestinal and metabolic balance, as they support homeostasis, strengthen …

20 - 80 years of age All Phase N/A

Population Pharmacokinetics of Anti-infectives in Critically Ill Children

Concentrations and effects of anti-infectives in critically ill children are unpredictable and the risk of under-exposure may be associated with poor clinical outcomes. In addition, between-subject variability (BSV) is known to be substantial in critically ill children. Rationalisation of anti-infectives in children is therefore desirable. The investigators aim to investigate, …

1 - 18 years of age All Phase N/A

Morbidity and Mortality: Surgery and Standardized Transmission in Operating Room

The primary objective of the study is to evaluate the efficacy of standard handover with AnesList© between physician anesthesists in operating room, for a complete transmission for a patient, on the occurence of event as death, serious complications or rehospitalization in month of postoperative after major surgery.

18 years of age All Phase N/A
L Laurent Salomon, MD, PhD

LUMIERE on the FETUS

Congenital anomalies are a major public health problem. They affect 2-3% of births, around 20,000 new cases per year in France, of which 15% are cared for in Ile de France. These congenital anomalies are a major cause of morbidity, infant mortality and disability. They are also a major cause …

18 years of age Female Phase N/A
O Olivier Merigot de Treigny

AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer

The AFU has set itself the task of setting up a register of medical practices in order to define possible improvements in the therapeutic management and follow-up of NMIBC. In order to obtain representative data, all urologists who are members of the AFU may be invited to include their patients.

18 years of age All Phase N/A

Simplify language using AI